Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Chinese patients with progressive fibrosing ILDs
NCT05065190Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2021
- Primary completion
- Apr 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of nintedanib in Chronic fibrosing interstitial lung disease (PF-ILD), sponsored by Boehringer Ingelheim. Started Nov 2021; status: completed.
02
Drugs
nintedanib
03
Conditions
Chronic fibrosing interstitial lung disease (PF-ILD)
Beyond the preview
Go deeper on NCT05065190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065190.